Glaukos Corp (GKOS) - Total Assets
Based on the latest financial reports, Glaukos Corp (GKOS) holds total assets worth $999.38 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GKOS book value for net asset value and shareholders' equity analysis.
Glaukos Corp - Total Assets Trend (2012–2024)
This chart illustrates how Glaukos Corp's total assets have evolved over time, based on quarterly financial data.
Glaukos Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Glaukos Corp's total assets of $999.38 Million consist of 46.1% current assets and 53.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.4% |
| Accounts Receivable | $60.74 Million | 6.2% |
| Inventory | $57.68 Million | 5.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $263.44 Million | 27.0% |
| Goodwill | $66.13 Million | 6.8% |
Asset Composition Trend (2012–2024)
This chart illustrates how Glaukos Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Glaukos Corp (GKOS) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Glaukos Corp's current assets represent 46.1% of total assets in 2024, a decrease from 68.2% in 2012.
- Cash Position: Cash and equivalents constituted 17.4% of total assets in 2024, down from 33.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 27.0% of total assets.
Glaukos Corp Competitors by Total Assets
Key competitors of Glaukos Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Vitrolife AB
ST:VITR
|
Sweden | Skr11.12 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.00 Billion |
|
Lumos Diagnostics Holdings Ltd
AU:LDX
|
Australia | AU$20.81 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
|
Ok Biotech Co Ltd
TW:4155
|
Taiwan | NT$3.89 Billion |
|
Promimic AB
ST:PRO
|
Sweden | Skr75.71 Million |
|
Memphasys Ltd
AU:MEM
|
Australia | AU$10.45 Million |
Glaukos Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.20 | 5.54 | 9.45 |
| Quick Ratio | 4.47 | 4.71 | 9.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $367.25 Million | $325.60 Million | $419.74 Million |
Glaukos Corp - Advanced Valuation Insights
This section examines the relationship between Glaukos Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.14 |
| Latest Market Cap to Assets Ratio | 6.42 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | $974.76 Million |
| Market Capitalization | $6.26 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Glaukos Corp's assets at a significant premium (6.42x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Glaukos Corp's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Glaukos Corp (2012–2024)
The table below shows the annual total assets of Glaukos Corp from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $974.76 Million | +3.65% |
| 2023-12-31 | $940.41 Million | -12.45% |
| 2022-12-31 | $1.07 Billion | -4.84% |
| 2021-12-31 | $1.13 Billion | +12.27% |
| 2020-12-31 | $1.01 Billion | +22.86% |
| 2019-12-31 | $818.40 Million | +295.42% |
| 2018-12-31 | $206.97 Million | +24.80% |
| 2017-12-31 | $165.84 Million | +23.42% |
| 2016-12-31 | $134.37 Million | +15.18% |
| 2015-12-31 | $116.66 Million | +348.33% |
| 2014-12-31 | $26.02 Million | -15.73% |
| 2013-12-31 | $30.88 Million | +497.81% |
| 2012-12-31 | $5.17 Million | -- |
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathw… Read more